Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) insider Derek J. Maetzold sold 1,947 shares of Castle Biosciences stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $20.35, for a total value of $39,621.45. Following the completion of the sale, the insider now owns 65,418 shares of the company’s stock, valued at $1,331,256.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Castle Biosciences Trading Down 0.5 %
Shares of CSTL opened at $18.84 on Thursday. Castle Biosciences, Inc. has a 12 month low of $9.26 and a 12 month high of $26.70. The stock has a fifty day moving average price of $21.71 and a 200-day moving average price of $19.83. The firm has a market cap of $517.16 million, a PE ratio of -8.72 and a beta of 0.93.
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.74. The business had revenue of $66.12 million during the quarter, compared to the consensus estimate of $51.32 million. Castle Biosciences had a negative return on equity of 14.92% and a negative net margin of 26.15%. As a group, research analysts forecast that Castle Biosciences, Inc. will post -2.41 EPS for the current year.
Institutional Investors Weigh In On Castle Biosciences
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the stock. Scotiabank upped their price target on shares of Castle Biosciences from $33.00 to $37.00 and gave the stock a “sector outperform” rating in a research report on Friday, March 1st. KeyCorp increased their target price on Castle Biosciences from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, March 1st.
Read Our Latest Research Report on CSTL
About Castle Biosciences
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Further Reading
- Five stocks we like better than Castle Biosciences
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- United Airlines Soars on Earnings Beat
- Manufacturing Stocks Investing
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Are Penny Stocks a Good Fit for Your Portfolio?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.